In The News: Department of Brain Health

The Science Times

A week ago, Brigham and Women's Hospital announced it would spearhead the first human trial of a nasal spray vaccine as a protection against Alzheimer's disease, formulated to prevent or delay the progression of the disease.

Suara.com

Last week, Brigham and Women's Hospital announced that it would pioneer a trial using a spray drug for Alzheimer's disease.

True Viral News

Alzheimer's treatments were not considered likely just months ago.

Business Insider

Alzheimer's treatments seemed like an unlikely prospect just months ago.

KLAS-TV: 8 News Now

A recently approved medication for Alzheimer’s disease is making headlines because of its price tag. It costs $56,000 a year.

Neurology Live

Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

MarketScreener

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

VAntage Point

Andrew Ho joined the Air Force in 2010.

KLAS-TV: 8 News Now

More than 1100 people filled the Las Vegas Ballpark Saturday morning for the annual Alzheimer’s Association Walk to End Alzheimer’s.

Yahoo!

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.

New Atlas

Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.

The Scientist

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.